Annual report pursuant to Section 13 and 15(d)

Intangible Assets

v3.20.4
Intangible Assets
 12 Months Ended
Sep. 30, 2020
Intangible Assets  
Intangible Assets

7. Intangible Assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

    

As of September 30, 

 

 

2020

 

2019

Clinical trial data

 

$

250,000

 

$

250,000

Accumulated amortization

 

 

(250,000)

 

 

(104,167)

Intangible assets, net

 

$

 —

 

$

145,833

 

Amortization expense for the years ended September 30, 2020 and 2019 was approximately $0.1 million and $0.1 million, respectively.